PureHale® & The Future of Fine Mist Dispensers for Upper Airway Treatments

Nasal saline treatments can provide symptomatic relief for a range of upper airway conditions such as allergies, sinusitis, dry mucosa, dry nose as well as viral or bacterial infections. The inflammation of the nasal tissues in the upper airway can cause discomfort or irritation in people of all ages. Consumers are becoming increasingly interested in upper airway treatments that can help to prevent or relieve these symptoms in a convenient-to-use and portable format. Currently, there are a wide range of delivery technologies used to treat upper airway conditions, ranging from the simple dropper or nasal rinses to more complex sprays or aerosol dispensers. But are these delivery systems able to target the desired regions of the upper airways?  We’ll discuss the properties of delivery systems that may be able to meet this need.

It’s not the delivery system per se that impacts the product’s ability to target specific regions of the respiratory system. The produced droplet size has a considerable impact on delivering fine mist product where it’s needed most. Julian and Giulia discuss some of the critical scientific data that should be studied and considered in early development activities that can have an impact on fine mist delivery device selection.

Market research shows that consumers have an increasing interest in natural, non-chemical products that can provide soothing, cleaning and moisturizing effects on the upper airway. We’ll discuss if natural saline based products delivered by a fine mist can provide the relief they are seeking. Find out more as our experts outline a few of the benefits of saline solutions for upper airway treatments.

Using the right delivery technology is another key component to developing successful upper airways products. Consumers are drawn to non-invasive and convenient portable delivery systems such as nasal mists. And Aptar Pharma’s PureHale^®; is an advanced upper airway delivery system meeting such requirements. Learn more about how Aptar Pharma scientists determine customer formulation compatibility with PureHale^® delivery systems during the development process to accelerate and derisk development. Aptar Pharma and its subsidiaries can provide the specialized analytical testing services required for inhaled fine mist products. Not only can Aptar Pharma offer global supply of Purehale^® at scale, but it also provides customized technical support to help product companies manufacture their products with ease.

Discover the reliability of the PureHale^® system, using Aptar Pharma’s compressed air driven Bag-On-Valve (BOV) technology that delivers a consistent fine mist for an extended period of continuous operation. This advanced technology not only provides targeted delivery, but also delivers convenience and portability, in both optional mask and mouthpiece configurations.

With a clean and easy dispensing system, PureHale^® technology is receiving growing interest from parents of infants and toddlers. Ideal for non-chemical treatments, saline-based PureHale^® mist products can deliver cleaning and moisturizing effects to the upper airways. Learn more about the benefits of inhaled saline products in children through recent research studies and market analysis.

With the PureHale^® delivery technology new possibilities for a range of different applications and categories can be expected to open up for new developments. From scented mists, personal care products, to upper respiratory tract and anti-viral treatments, further research may show PureHale^® respiratory delivery systems to be worthy of future applications in these areas.

Learn more about the global markets with the most interest in fine mist delivery pathways using Aptar Pharma’s differentiated PureHale^® technology in this engaging interview with two of Aptar’s leading experts in the field. Published in the November 2024 issue of On Drug Delivery (ONDD) PureHale^® & The Future of Fine Mist Dispensers for Upper Airway Treatments, delves into the details of what is driving the fine mist product delivery market, and how PureHale^® may be the right technology for many of tomorrow’s upper airway solutions.